Perréard, Marion
Florent, Romane
Divoux, Jordane
Grellard, Jean-Michel
Lequesne, Justine
Briand, Mélanie
Clarisse, Bénédicte
Rousseau, Nathalie
Lebreton, Esther
Dubois, Brice
Harter, Valentin
Lasne-Cardon, Audrey
Drouet, Julien
Johnson, Alisson
Le Page, Anne-Laure
Bazille, Céline
Jeanne, Corinne
Figeac, Martin
Goardon, Nicolas
Vaur, Dominique
Micault, Emmanuel
Humbert, Maxime
Thariat, Juliette
Babin, Emmanuel
Poulain, Laurent
Weiswald, Louis-Bastien
Bastit, Vianney
Funding for this research was provided by:
Fonds de dotation Patrick Brou de Laurière (CD 48/FDPBL/2021, CD 48/FDPBL/2021)
Groupement des Entreprises Françaises dans la lutte contre le Cancer
Normandy County Council / European Union (ORGATHEREX)
Article History
Received: 11 January 2023
Accepted: 28 February 2023
First Online: 9 March 2023
Declarations
:
: This study has received ethical approval from the Comité de Protection des Personnes Est III (N°EudraCT: 2019–A03332-55) in February 2020 with last amendment (V4) accepted in June 2021. This committee is independent and not related with any affiliation of the authors. Any subsequent will of modification of the protocol would be submitted to agreement of the committee. The clinical trial has been registered at ClinicalTrials.gov with the identifier NCT04261192 on February 7th 2020. The study will be explained to the patients by the ENT surgeons or the oncologists, who will give them an information file. All patients will consent to be part of the study by giving their informed non-opposition.
: Not applicable.
: The authors declare no competing interests.